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Background: Protect II study evaluated the effect of circulatory support with Impella vs
Intra aortic balloon pump (IABP) in high risk patients undergoing high risk PCI with
depressed LV function and complex anatomy. The results of the study were confounded
by an imbalanced and more vigorous use of rotational atherectomy(RA) in the Impella
arm which made the interpretation of the composite endpoint difficult. We sought to
evaluate the safety and effectiveness of Impella 2.5 in high risk percutaneous coronary
intervention (HRPCI) compared to the IABP in a more homogeneous population, without
the confounding effect of RA.
Methods: A total of 375 eligible patients underwent HRPCI without the use of rotational
atherectomy (88% Protect II study). A composite of 10 major adverse events (MAE)
endpoint including death, myocardial infarction, stroke, any repeat revascularization, was
assessed at 30 and 90 days.
Results: Baseline and procedural characteristics were balanced between the study arms: age
67 10 years old, 86% CHF, 51% diabetes, 67% had prior myocardial infarction, and 26%
renal insufficiency. The LVEF was 246, STS mortality was 5.66 and Syntax was 2912.
Patients treated with the Impella device had significant improved outcomes at 30 day and 90
day compared to IABP arm ( 29.3% vs 41.9%, p0.011 and 35.5% vs 50.5%, p0.003).
Conclusions: Patients undergoing high risk PCI supported with Impella had superior
outcomes compared to those with IABP.
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Background: We evaluated the impact of paclitaxel-coated balloon angioplasty for
treatment of drug-eluting stent restenosis compared with uncoated balloon angioplasty
alone. (NCT00998439).
Methods: In this prospective, single-blind, multicenter, trial we randomly assigned 110
patients with Instent-Restnosis of drug eluting stents to undergo treatment either with paclitaxel
coated balloon (SeQuent Please, BBraun, Melsungen) or balloon angioplasty alone. Primary
endpoint was in-stent late lumen loss at 6 months. Secondary clinical endpoint was composited
of cardiac death, myocardial infarction attributed to the target vessel or TLR.
Results: There was no difference in patient baseline characteristics. Lesion length was
11.26.5mm in the DCB- and 12.28.2mm in the POBA-group (pn.s). Post PCI, for
the stented segment and the total segment minimal lumen diameter and diameter stenosis
were not different. Clinical follow-up after 12 months was 100%. Treatment with DCB
was superior to balloon angioplasty alone with an in-stent late loss of 0.430.61mm vs.
1.030.77mm (p0.001). Minimal lumen diameter was significantly larger and percent
diameter stenosis significantly lower with use of the DCB for both the stented and total
segment. Restenosis rate was reduced from 58.1% to 17.2% (P0.001) and the clinical
endpoint at 6 months was reduced from 50% to 16.7% (P0.001), respectively. After 12
months the effect of DCB persisted (clinical endpoint 52.6% vs. 16.7%; p0.001 and TLR
36.8% vs. 15.3%, p0.005, respectively). There was one probable stent thrombosis in the
POBA group. Clinical follow-up after 2 years will be completed in May 2013 and presented.
Conclusions: Paclitaxel coated balloon angioplasty was superior to balloon angioplasty
alone for the treatment of instent-restenosis of drug-eluting stents. The favorable effects of
the DCB-therapy persisted over 12 months.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), Everolimus-eluting stent (EES) and SeQuent™ Please, a
drug-eluting balloon (DEB) on the outcome of patients with diffuse in-stent restenosis
(D-ISR) after bare metal stent (BMS) implantation.
Methods: A prospective analysis of 1078 patients with 1251 D-ISR lesions (427 SES,
363 PES, 232 EES and 229 DEB) in six high volume Asian centers after successful stent
implantation (SES: LAD 45.7%, LCX 27.9%, RCA 26.4%) (PES: LAD 46.0%, LCX
22.9%, RCA 31.1%) (EES: LAD 50.0%, LCX 21.0%, RCA 29.0%) (DEB: LAD 54.0%,
LCX 23.0%, RCA 23.0%) was performed. The study endpoints were major adverse
cardiac events (MACE) and target lesion revascularization (TLR) at 12 and 24 months.
Results: See table for clinical results.
Conclusions: (1) The use of SES, PES, EES and DEB in patients with D-ISR seems to
be favorable in terms of in-hospital clinical outcome. (2) Patients treated with DEB
showed higher restenosis rate and TLR compared with DES.
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Background: Effect of intravascular ultrasound (IVUS)-guided complex approaches
using drug-eluting stent (DES) for coronary bifurcation lesions on clinical outcome has
been not yet studied.The present study aimed to analyze the difference in one-year
outcome after two-stent techniques with the implantation of DES for coronary bifurcation
lesions between IVUS-guided versus angiography-guided groups.
Methods: From May 26, 2007 to March 24, 2010, 628 patients received two-stent
techniques (324 in IVUS-guided, 304 in Angio-guided group) were prospectively studied.
We compared the major adverse cardiac event (MACE, including cardiac death, stent
thrombosis [ST], myocardial infarction[MI], target lesion/vessel revascularization)at
12-month follow-up, before and after adjusting by using propensity score matching.
Results: By 12-month after indexed procedure, patients in the Angio-guided group had
significantly increased in-stent restenosis. The unadjusted late ST rate was 6.9%, 5.3%
and 4.3% in the Angio-guided group was 4.3%, significantly different to 0.6% in the
IVUS-guided group (p0.003),1.2% 0.6% and this translated into the significant
differences in overall (6.9% vs. 1.2%, p0.001) and definite (5.3% vs. 0.6%, p0.001)
ST, MI (8.9% vs. 4.6%, p0.038) and cardiac death (3.3% vs. 0.9%, p0.049) between
two groups. By propensity score matching, 123 paired patients were matched, the late ST
at 12-month follow-up was 4.9% in Angio-guided group, and it was 0% in the
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